Compare · NVS vs SCTL
NVS vs SCTL
Side-by-side comparison of Novartis AG (NVS) and Societal CDMO Inc. (SCTL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and SCTL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS carries a market cap of $282.64B.
- NVS has hit the wire 1 time in the past 4 weeks while SCTL has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 0 for SCTL).
- Company
- Novartis AG
- Societal CDMO Inc.
- Price
- $152.08+2.69%
- $1.09+0.46%
- Market cap
- $282.64B
- -
- 1M return
- +2.61%
- -
- 1Y return
- +28.88%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 1
- 0
- Recent ratings
- 25
- 0
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Societal CDMO Inc.
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
Latest SCTL
- SEC Form 15-12G filed by Societal CDMO Inc.
- SEC Form EFFECT filed by Societal CDMO Inc.
- SEC Form EFFECT filed by Societal CDMO Inc.
- SEC Form EFFECT filed by Societal CDMO Inc.
- SEC Form SC 13D/A filed by Societal CDMO Inc. (Amendment)
- Arens Mathew Paul closing all direct ownership in the company (SEC Form 4)
- Weisman Wayne returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)
- Reasons Bryan M. returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)
- Parks Laura L. returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)
- Miller James Charles returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)